Vanguard Personalized Indexing Management LLC Acquires 11,609 Shares of Moderna, Inc. $MRNA

Key Points

• Vanguard Personalized Indexing Management LLC increased its holdings in Moderna by 28% during the second quarter, acquiring 11,609 additional shares, which brings their total to 53,103 shares valued at approximately $1.47 million.
• Moderna's stock is currently down 4.2% and has a market cap of $10.16 billion, with a recent trading price of $26.01, alongside a 12-month range between $23.15 and $57.69.
• For its latest quarter, Moderna reported an EPS of ($2.13), beating estimates, but its revenue fell 41.1% year-over-year to $142 million.

Vanguard Personalized Indexing Management LLC lifted its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 28.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 53,103 shares of the company's stock after purchasing an additional 11,609 shares during the quarter. Vanguard Personalized Indexing Management LLC's holdings in Moderna were worth $1,465,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. S Bank Fund Management Ltd acquired a new stake in shares of Moderna during the first quarter worth about $25,000. TD Private Client Wealth LLC raised its position in shares of Moderna by 348.8% during the second quarter. TD Private Client Wealth LLC now owns 956 shares of the company's stock worth $26,000 after purchasing an additional 743 shares during the period. SVB Wealth LLC acquired a new stake in shares of Moderna during the first quarter worth about $28,000. CX Institutional raised its position in shares of Moderna by 1,129.8% during the second quarter. CX Institutional now owns 1,033 shares of the company's stock worth $29,000 after purchasing an additional 949 shares during the period. Finally, Costello Asset Management INC acquired a new stake in shares of Moderna during the first quarter worth about $30,000. Institutional investors and hedge funds own 75.33% of the company's stock.

Moderna Stock Down 4.2%

Shares of NASDAQ:MRNA opened at $26.01 on Friday. Moderna, Inc. has a 12-month low of $23.15 and a 12-month high of $57.69. The stock has a market cap of $10.16 billion, a PE ratio of -3.45 and a beta of 2.01. The business has a 50 day moving average of $25.91 and a 200-day moving average of $27.09.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings data on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.99) by $0.86. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The company had revenue of $142.00 million during the quarter, compared to analysts' expectations of $116.26 million. During the same quarter in the previous year, the company posted ($3.33) earnings per share. The business's revenue was down 41.1% on a year-over-year basis. Moderna has set its FY 2025 guidance at EPS. Equities research analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current year.

Wall Street Analyst Weigh In

MRNA has been the topic of a number of research analyst reports. Bank of America dropped their price target on Moderna from $26.00 to $25.00 and set an "underperform" rating on the stock in a research report on Tuesday, July 22nd. Morgan Stanley lifted their price target on Moderna from $31.00 to $32.00 and gave the company an "equal weight" rating in a research note on Friday, October 10th. JPMorgan Chase & Co. set a $26.00 price target on Moderna in a research note on Friday, August 1st. Weiss Ratings reissued a "sell (e+)" rating on shares of Moderna in a research note on Wednesday, October 8th. Finally, Evercore ISI set a $32.00 price target on Moderna in a research note on Friday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, twelve have given a Hold rating and five have issued a Sell rating to the company. According to MarketBeat.com, Moderna currently has a consensus rating of "Hold" and a consensus price target of $39.93.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.